70 related articles for article (PubMed ID: 20185420)
1. Plasma DNA level in predicting therapeutic efficacy in advanced nonsmall cell lung cancer.
Kumar S; Guleria R; Singh V; Bharti AC; Mohan A; Das BC
Eur Respir J; 2010 Oct; 36(4):885-92. PubMed ID: 20185420
[TBL] [Abstract][Full Text] [Related]
2. Plasma nucleosome levels might predict response to therapy in patients with advanced non-small-cell lung cancer.
Kumar S; Guleria R; Singh V; Bharti AC; Mohan A; Das BC
Clin Lung Cancer; 2010 Jan; 11(1):36-44. PubMed ID: 20085866
[TBL] [Abstract][Full Text] [Related]
3. Lack of utility of plasma TNF-alpha level in predicting therapeutic efficacy in patients with advanced non-small cell lung cancer.
Kumar S; Guleria R; Singh V; Mohan A; Bharti AC; Das BC
Cytokine; 2010 Sep; 51(3):245-8. PubMed ID: 20599393
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of plasma TGF-β1 level in predicting therapeutic efficacy and prognosis in patients with advanced non-small cell lung cancer.
Kumar S; Guleria R; Mohan A; Singh V; Bharti AC; Das BC
Cancer Invest; 2011 Mar; 29(3):202-7. PubMed ID: 21280981
[TBL] [Abstract][Full Text] [Related]
5. Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer.
Holdenrieder S; Stieber P; von Pawel J; Raith H; Nagel D; Feldmann K; Seidel D
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):5981-7. PubMed ID: 15447981
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of circulating plasma DNA as a diagnostic tool for advanced non-small cell lung cancer and its predictive utility for survival and response to chemotherapy.
Kumar S; Guleria R; Singh V; Bharti AC; Mohan A; Das BC
Lung Cancer; 2010 Nov; 70(2):211-7. PubMed ID: 20181407
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of plasma vascular endothelial growth factor in monitoring first-line chemotherapy in patients with advanced non-small cell lung cancer.
Kumar S; Guleria R; Singh V; Bharti AC; Mohan A; Das BC
BMC Cancer; 2009 Dec; 9():421. PubMed ID: 19958548
[TBL] [Abstract][Full Text] [Related]
8. C-reactive protein as a monitor of chemotherapy response in advanced non-small cell lung cancer (CML study).
Srimuninnimit V; Ariyapanya S; Nimmannit A; Wonglaksanapimon S; Akewanlop C; Soparattanapaisarn N
J Med Assoc Thai; 2012 Feb; 95 Suppl 2():S199-207. PubMed ID: 22574550
[TBL] [Abstract][Full Text] [Related]
9. Predictive role of plasma vascular endothelial growth factor for the effect of celecoxib in advanced non-small cell lung cancer treated with chemotherapy.
Sörenson S; Fohlin H; Lindgren A; Lindskog M; Bergman B; Sederholm C; Ek L; Lamberg K; Clinchy B
Eur J Cancer; 2013 Jan; 49(1):115-20. PubMed ID: 22951014
[TBL] [Abstract][Full Text] [Related]
10. Serum carcinoembryonic antigen level as a surrogate marker for the evaluation of tumor response to chemotherapy in nonsmall cell lung cancer.
Ishiguro F; Fukui T; Mori S; Katayama T; Sakakura N; Hatooka S; Mitsudomi T
Ann Thorac Cardiovasc Surg; 2010 Aug; 16(4):242-7. PubMed ID: 21057440
[TBL] [Abstract][Full Text] [Related]
11. Correlation of therapeutic outcome in non-small cell lung cancer and DNA damage assayed by polymerase chain reaction in leukocytes damaged in vitro.
Oshita F; Yamamoto N; Fukuda M; Ohe Y; Tamura T; Eguchi K; Shinkai T; Saijo N
Cancer Res; 1995 Jun; 55(11):2334-7. PubMed ID: 7757984
[TBL] [Abstract][Full Text] [Related]
12. Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response.
Vollmer RT; Govindan R; Graziano SL; Gamble G; Garst J; Kelley MJ; Christenson RH
Clin Cancer Res; 2003 May; 9(5):1728-33. PubMed ID: 12738727
[TBL] [Abstract][Full Text] [Related]
13. Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer.
Holdenrieder S; von Pawel J; Dankelmann E; Duell T; Faderl B; Markus A; Siakavara M; Wagner H; Feldmann K; Hoffmann H; Raith H; Nagel D; Stieber P
Clin Cancer Res; 2008 Dec; 14(23):7813-21. PubMed ID: 19047109
[TBL] [Abstract][Full Text] [Related]
14. Nucleosomes and CYFRA 21-1 indicate tumor response after one cycle of chemotherapy in recurrent non-small cell lung cancer.
Holdenrieder S; von Pawel J; Dankelmann E; Duell T; Faderl B; Markus A; Siakavara M; Wagner H; Feldmann K; Hoffmann H; Raith H; Nagel D; Stieber P
Lung Cancer; 2009 Jan; 63(1):128-35. PubMed ID: 18571761
[TBL] [Abstract][Full Text] [Related]
15. Early and specific prediction of the therapeutic efficacy in non-small cell lung cancer patients by nucleosomal DNA and cytokeratin-19 fragments.
Holdenrieder S; Stieber P; VON Pawel J; Raith H; Nagel D; Feldmann K; Seidel D
Ann N Y Acad Sci; 2006 Sep; 1075():244-57. PubMed ID: 17108218
[TBL] [Abstract][Full Text] [Related]
16. Study of pretreatment serum levels of HER-2/neu oncoprotein as a prognostic and predictive factor in patients with advanced nonsmall cell lung carcinoma.
Ardizzoni A; Cafferata MA; Paganuzzi M; Filiberti R; Marroni P; Neri M; Fontana V; Nicoló G; Perdelli L; Stampino CG; Rosso R; Puntoni R
Cancer; 2001 Oct; 92(7):1896-904. PubMed ID: 11745263
[TBL] [Abstract][Full Text] [Related]
17. [Aberrant methylation of circulating DNA for prediction of chemo-sensitivity of non-small cell lung cancer].
Takai D
Gan To Kagaku Ryoho; 2010 Feb; 37(2):189-93. PubMed ID: 20154471
[TBL] [Abstract][Full Text] [Related]
18. Can plasma DNA monitoring be employed in personalized chemotherapy for patients with advanced lung cancer?
Pan S; Xia W; Ding Q; Shu Y; Xu T; Geng Y; Lu Y; Chen D; Xu J; Wang F; Zhao C; Huang P; Huang P; Shen H; Hu Z; Lu S
Biomed Pharmacother; 2012 Mar; 66(2):131-7. PubMed ID: 22401927
[TBL] [Abstract][Full Text] [Related]
19. Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy.
Gautschi O; Bigosch C; Huegli B; Jermann M; Marx A; Chassé E; Ratschiller D; Weder W; Joerger M; Betticher DC; Stahel RA; Ziegler A
J Clin Oncol; 2004 Oct; 22(20):4157-64. PubMed ID: 15483026
[TBL] [Abstract][Full Text] [Related]
20. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer.
Simon G; Sharma A; Li X; Hazelton T; Walsh F; Williams C; Chiappori A; Haura E; Tanvetyanon T; Antonia S; Cantor A; Bepler G
J Clin Oncol; 2007 Jul; 25(19):2741-6. PubMed ID: 17602079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
